Peripheral T-cell Lymphoma  >>  Campath (alemtuzumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Campath (alemtuzumab) / Sanofi
A-CHOP-14, NCT00725231: Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Unknown status
3
274
Europe
alemtuzumab, monoclonal anti CD52 antibody, chemotherapy, chemotherapy cylcophosphamide, hydroxyldaunorubicin
University of Göttingen, German High-Grade Non-Hodgkin's Lymphoma Study Group, Nordic Lymphoma Group
Peripheral T Cell Lymphoma, Unspecified, Angioimmunoblastic Lymphadenopathy, Extranodal NK/T-cell Lymphoma
03/14
03/14
ACT-1, NCT00646854 / 2006-006130-17: Alemtuzumab and CHOP in T-cell Lymphoma

Checkmark P3 data-ASH
Nov 2012 - Nov 2012: P3 data-ASH
Completed
3
136
Europe, RoW
CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab, CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
Aarhus University Hospital, GCP-unit at Aarhus University Hospital, Aarhus, Denmark
Lymphoma, T-Cell, Peripheral
12/16
12/16

Download Options